摘要
目的探讨联合吸入噻托溴铵和沙美特罗替卡松对慢性阻塞性肺疾病(COPD)的疗效观察。方法 128例中重度COPD稳定期患者随机分为四组:联合治疗组给予吸入噻托溴铵干粉与沙美特罗替卡松;噻托溴铵组给予吸入噻托溴铵干粉;沙美特罗替卡松组给予吸入沙美特罗替卡松;空白组给予常规治疗。观察患者的肺功能变化、急性发作次数和不良反应。结果在治疗结束时,三组治疗组与空白组相比较,第1秒用力肺活量(FEV1)显著提高,急性发作次数明显下降,不良反应无明显增加;联合治疗组分别与噻托溴铵组及沙美特罗替卡松组比较,FEV1显著提高,急性发作次数显著下降,各组不良反应均无明显增加。结论噻托溴铵和沙美特罗替卡松联合吸入能够显著改善COPD患者的肺功能,降低急性发作次数,而不良反应无明显增加,值得临床推广。
Objective To investigate the therapeutic effects of combined inhalation of Tiotropium Bromide and Salmeterol/Fluticasone propionate in chronic obstructive pulmonary diseases（COPD）.Methods 128 cases of moderate to severe stable COPD were randomly divided into 4 groups： the combined treatment group were treated with Tiotropium Bromide and Salmeterol /Fluticasone;the Tiotropium Bromide group were treated with Tiotropium Bromide;the Salmeterol /Fluticasone were treated with Salmeterol /Fluticasone;the control group was given routine treatment.Changes in patient lung function,acute episode and adverse reaction were observed.Results At the end of treatment,compared with blank group,FEV1 improved significantly,the number of acute episodes decreased significantly and no significant increase in adverse reactions in all three treatment groups.Conclusion Tiotropium Bromide and salmeterol/fluticasone propionate combined inhaled treatment in COPD patients can significantly improve lung function and reduce acute episodes,while no significant increase in adverse events was observed.The combined treatment seems worthy of consideration for clinical application.
出处
《中国医药指南》
2012年第3期44-45,共2页
Guide of China Medicine
关键词
慢性阻塞性肺疾病
噻托溴铵
沙美特罗替卡松
Chronic obstructive pulmonary diseases
Tiotropium
Bromide Salmeterol /Fluticasone
